Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced...

Area of Science:

• Cardiovascular Research
• Pharmacology
• Atherosclerosis Research

Background:

• The renin-angiotensin system (RAS) plays a key role in cardiovascular regulation.
• RAS inhibition is a known strategy for reducing atherosclerosis.
• Direct comparisons of different RAS inhibition methods are lacking.

Purpose of the Study:

• To compare the efficacy of three pharmacological RAS inhibition strategies: renin inhibitors, ACE inhibitors, and angiotensin II type 1 receptor blockers.
• To determine the dose-response relationships of these inhibitors in reducing atherosclerosis.
• To evaluate their effects on blood pressure and atherosclerotic lesion development.

Main Methods:

• Male LDL receptor knockout mice were treated with vehicle or varying doses of aliskiren, enalapril, or losartan for 12 weeks.
• Mice were fed a high-fat diet throughout the study.
• Blood pressure, plasma lipids, plasma renin, and atherosclerotic lesion size were assessed.

Main Results:

• All three drug classes increased plasma renin concentrations.
• No significant changes in plasma cholesterol were observed.
• A dose-dependent reduction in blood pressure and atherosclerotic lesions was observed for all three drug types.
• The highest doses of each drug significantly reduced lesion size and renal angiotensin II concentrations without significant differences between the drug classes.

Conclusions:

• Pharmacological inhibition of the renin-angiotensin system effectively reduces atherosclerosis development.
• The mode of RAS inhibition (renin, ACE, or AT1 receptor blockade) does not influence the anti-atherosclerotic effect when doses are adjusted for efficacy.
• These findings highlight the importance of RAS inhibition in managing atherosclerosis in a dose-dependent manner.